Methods for treating respiratory viral infection
Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
1. A method of treating, ameliorating, or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection in a subject, comprising administering to the subject a compound, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, wherein the compound is
and wherein the respiratory viral infection is influenza infection, rhinovirus infection, coronavirus infection, or paramyxovirus infection.
2. The method of claim 1 , further comprising administering at least one second active agent.
3. The method of claim 2 , wherein the second active agent is an antiviral agent or an antibiotic agent.
4. The method of claim 1 , wherein the respiratory viral infection is influenza infection.
5. The method of claim 4 , wherein the influenza is type A influenza.
6. The method of claim 5 , wherein the type A influenza is of a subtype, selected from the group consisting of: H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7 subtypes.
7. The method of claim 4 , wherein the influenza is type B influenza.
8. The method of claim 4 , wherein the influenza is type C influenza.
9. The method of claim 1 , wherein the respiratory viral infection is rhinovirus infection.
10. The method of claim 1 , wherein the respiratory viral infection is coronavirus infection.
11. The method of claim 1 , wherein the respiratory viral infection is paramyxovirus infection.
12. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, is administered orally, parenterally, intranasally, or topically.
13. The method of claim 1 , wherein the subject is a human.
14. The method of claim 1 , wherein the stereoisomer of the compound is enantiomerically pure.
15. The method of claim 1 , wherein the compound is
16. The method of claim 15 , wherein the compound is enantiomerically pure.
17. The method of claim 1 , wherein the compound is
18. The method of claim 17 , wherein the compound is enantiomerically pure.
19. The method of claim 1 , wherein the compound is
20. The method of claim 19 , wherein the compound is enantiomerically pure.
21. The method of claim 1 , wherein the symptom associated with or resulting from the respiratory viral infection is fever, chills, sweating, headache, fatigue, tiredness, exhaustion, cough, runny nose, stuffy nose, sneezing, sore throat, body aches, muscle aches, joint pains, sinus pains, ear aches, chest pains, chest discomfort, sinus congestion, diarrhea, vomiting, abdominal pains, dehydration, or shortness of breath.
22. The method of claim 1 , wherein the treating, ameliorating, or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection results in a reduction in weight loss as compared to that in an untreated subject.
23. The method of claim 1 , wherein the treating, ameliorating, or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection results in reduced lung damage as compared to that in an untreated subject.
24. The method of claim 1 , wherein the treating, ameliorating, or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection results in a decreased viral load as compared to that in an untreated subject.